Singapore-based investor AngelCentral announced Wednesday its first successful BioTech syndicate by its members to invest in RyboDyn Inc., a US biotechnology company pioneering the development of immunotherapies targeting the dark genome.

This investment supports RyboDyn Inc’s Seed round which was backed by Genedant, SeaX Ventures, SOSV, and Swell VC, Massive Tech Ventures and P2V, AngelCentral said in a statement.

The funding will help RyboDyn Inc to accelerate platform execution, expand its proprietary dataset, and progress lead pipeline candidates into IND-enabling studies.

It is noted that conventional drugs rely on established protein targets like HER2 or EGFR, which many patients lack.

RyboDyn decodes the Dark Transcriptome to unlock an unexploited landscape of disease-specific proteins hidden within the 98 percent of the human genome historically dismissed as non-coding ‘junk’ DNA, which are sections of DNA do not contain direct recipes for those traditional, standard proteins.

This investment reflects strong conviction among top-tier biotech investors in startups leveraging artificial intelligence to unlock new frontiers in human biology, said the statement.

Through its proprietary platform, RyboDyn said it is opening up vital new therapeutic pathways for patients facing hard-to-treat cancers and limited treatment options, bringing much-needed hope to them.

“The emotional and financial impacts on families for these individuals are great,

“Rybodyn’s approach could eventually lead to drug developments with a significantly better safety profile and higher efficacy, potentially reducing the grueling side effects or offering new hope where current treatments are failing or are too painful to endure,” said Jeremy Tay, syndicate lead.

More corporate professionals becoming startup Founders – Angel Central